Recent Interviews

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company

Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential

Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain

18. August 2020 | 06:00 CET

BioNTech, CureVac, Valeo Pharma - who is the Covid-19 winner?

  • Covid-19

The two German companies BioNTech and CureVac have already provided investors with a considerable boost in share prices. The companies have come into the public eye in recent months because they are working on a vaccine against Covid-19 and have already made great progress. Worldwide, these two companies belong to the elite in research and are a beacon of hope in the fight against the corona pandemic. While BioNTech has been listed on the stock exchange for some time, CureVac made its stock market debut last Friday - with success. Investors who have so far missed their entry in these companies should have Valeo Pharma at least on their watch list.

time to read: 1 minutes by Mario Hose


Vaccine promises sales boost

The capital market places great hope in German life science companies. The market value of BioNTech is now over USD 16 billion and the newcomer to the stock exchange, CureVac, has already achieved a market capitalisation of over EUR 11 billion. For those who have not yet joined, Valeo Pharma is probably the next big opportunity for share price gains. The market value of the Canadian pharmaceutical company is currently CAD 73 million, which is still a long way from the billion-dollar valuation of the two German companies that are already involved with Covid-19.

Market launch in Canada with Valeo Pharma?

It will certainly only be a matter of time before Valeo Pharma launches a Covid-19 product in Canada. The company is focused on launching drugs in Canada. Biotech companies that have developed a drug in other parts of the world can then launch it in the North American country with Valeo Pharma. The pharmaceutical company does not conduct any research itself and is focused on licensing, approval and distribution of new drugs - which saves time and money. The company's representatives have direct access to doctors and can present new drugs and their effects to decision-makers without wastage.

Expertise for the Canadian market

While European pharmaceutical companies focus on the huge US market and US companies supply products to the EU market, Canada, with its 35 million or so inhabitants, is not in the industry's central focus because its large neighbour has more than ten times as many citizens. The big pharmaceutical giants still have their own sales force in Canada, but the smaller drug manufacturers use companies like Valeo to get the drugs to market.

Covid-19 vaccine in distribution

The special feature of Valeo Pharma is that around 70% of its shares are held by management, employees and insiders. Around CAD 8 million to finance the company has flowed into the cash box from these circles, which should indicate a high level of motivation. Valeo Pharma currently has eight products in its portfolio and six more in the pipeline. In view of the dynamics surrounding Covid-19, it should come as no surprise that the pharmaceutical company's employees will in future also be carrying vaccines against corona viruses in order to flush sales and profits into the cash register.

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

23. September 2020 | 09:05 CET

BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?

  • Covid-19

When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.


18. September 2020 | 06:00 CET

BioNTech, CureVac, EXMceuticals - reaching their goal with government support

  • Covid-19

In the fight against the spread of the Corona Pandemic, a great deal of commitment is required from companies. This situation also offers the opportunity to rethink and change existing work processes and procedures. Product ranges are being expanded and new possibilities and active ingredients are being sought to combat Covid-19. Above all, the common good of all is the primary focus of political institutions and for this reason they are not letting research-based companies down and are attracting them with special permits and subsidies. Ultimately, everyone around the world will likely benefit from this.


11. September 2020 | 09:59 CET

BioNTech, CureVac, Valeo Pharma - Growth after capital injection

  • Covid-19

Anyone working in the medical sector knows that the development of therapies and products usually costs a lot of time and especially a lot of money. In the race against the spread of the current Corona pandemic, there are major changes in the industry, because whoever comes to the market with a product first is de facto guaranteed high sales and profits. However, there is not much time left for the development of a vaccine against Covid-19 and to reduce the economic damage, researching companies have virtually unlimited amounts of money available. Whoever finds a solution against Covid-19 will certainly have the right team in the starting blocks in the fight against the subsequent Corona viruses.